(29 intermediate revisions by 5 users not shown) | |||
Line 4: | Line 4: | ||
<body> | <body> | ||
− | <div id="banner" style="background- | + | <div id="banner" style="background-image: url(https://static.igem.org/mediawiki/2016/thumb/6/64/Achievements.png/800px-Achievements.png);"></div> |
<div class="container-fluid content-main"> | <div class="container-fluid content-main"> | ||
Line 21: | Line 21: | ||
</li> | </li> | ||
<li> | <li> | ||
− | <a href="# | + | <a href="#Gold">Gold</a> |
</li> | </li> | ||
</ul> | </ul> | ||
Line 36: | Line 36: | ||
<div class="col-md-9 content-right" style="background-color: #fff;"> | <div class="col-md-9 content-right" style="background-color: #fff;"> | ||
− | < | + | <div class="pageTitle pageTitleOrange">Achievements</div> |
<section id="Achievements"> | <section id="Achievements"> | ||
+ | <img src="https://static.igem.org/mediawiki/2016/8/83/Happy_team_photo_Oxford_2016_Sam.jpeg" width="60%" /><figcaption>Most of the team at our banner at the Jamboree</figcaption> | ||
+ | <p><center><font size="5"> Our project was awarded a <font color="#FFD700"><b>GOLD</b></font> medal at the 2016 Jamboree. <br> We were nominated for: <b>Best Therapeutic Project</b>, | ||
+ | <br> | ||
+ | <b>Best Wiki</b>, | ||
+ | <b>Best Presentation</b> and <br> | ||
+ | <b>Best Education & Public Engagement!</b></center></font></p> | ||
<ul> | <ul> | ||
− | <li> | + | <li> Developed an initial proof of concept for a Wilson’s Disease therapeutic as an alternative to current treatments, which have problems associated with their cost, side-effects and high dosage frequency. </li> |
− | <li> | + | <li>We added 13 new BioBrick parts to the iGEM registry. |
Check our <a href="https://2016.igem.org/Team:Oxford/Parts">parts page</a> for more information.</li> | Check our <a href="https://2016.igem.org/Team:Oxford/Parts">parts page</a> for more information.</li> | ||
− | <li>We investigated several different promoters | + | <li>We investigated several different promoters and two different copper chelators with the aim of finding the most effective system. |
− | <li>We successfully designed composite parts with a copper chelator under control of a copper-sensitive promoter | + | <li>We successfully designed composite parts with a copper chelator under control of a copper-sensitive promoter. |
Check out our <a href="https://2016.igem.org/Team:Oxford/Results#subB">results page</a> for more information.</li> | Check out our <a href="https://2016.igem.org/Team:Oxford/Results#subB">results page</a> for more information.</li> | ||
− | <li>Discussions with the wider community played a major role in our project. We spoke to doctors and patients about Wilson’s Disease and used their feedback to guide our project. Check out our <a href=" https://2016.igem.org/Team:Oxford/ | + | <li>Discussions with the wider community played a major role in our project. We spoke to doctors and patients about Wilson’s Disease and used their feedback to guide our project. Check out our <a href=" https://2016.igem.org/Team:Oxford/Human_Practices"> Human Practices Hub</a> for more information.</li> |
</ul> | </ul> | ||
</section> | </section> | ||
Line 55: | Line 61: | ||
</div> | </div> | ||
<p> | <p> | ||
− | We’re ready for Boston in every way after the summer of our lives. Counting down the days to the Giant Jamboree! | + | We’re ready for Boston in every way after the summer of our lives. Counting down the days to the Giant Jamboree! |
</p><br> | </p><br> | ||
<div class="h4Purple"> | <div class="h4Purple"> | ||
Line 73: | Line 79: | ||
</div> | </div> | ||
<p> | <p> | ||
− | + | BBa_K1980000 and BBa_K1980001 are both are new to the Registry. Find out more about them on our <a href="https://2016.igem.org/Team:Oxford/Parts"> Parts </a> page. | |
</p> | </p> | ||
</section> | </section> | ||
Line 82: | Line 88: | ||
Experimentally validate that at least one new BioBrick Part or Device of your own design and construction works as expected.</div> | Experimentally validate that at least one new BioBrick Part or Device of your own design and construction works as expected.</div> | ||
<p> | <p> | ||
− | + | BBa_K1980003, BBa_K1980005, BBa_K1980007, BBa_K1980008 and BBa_K1980012 work as expected, hooray! See more information <a href="https://2016.igem.org/Team:Oxford/Results#subB">here.</a> | |
</p><br> | </p><br> | ||
<div class="h4Purple"> | <div class="h4Purple"> | ||
Convince the judges you have helped any registered iGEM team from high school, a different track, another university, or another institution in a significant way.</div> | Convince the judges you have helped any registered iGEM team from high school, a different track, another university, or another institution in a significant way.</div> | ||
<p> | <p> | ||
− | We carried out | + | We carried out all of the modelling for the Vilnius-Lithuania iGEM team, which can be seen on their <a href="https://2016.igem.org/Team:Vilnius-Lithuania/Collaborations#">wiki.</a> Additionally, we carried out a joint survey with the team, who have also been investigating a potential probiotic therapeutic, to investigate the perspectives of different cultures to probiotics and their application. <p> |
+ | |||
+ | We sent XMU China parts generated by last year’s Oxford iGEM team that they had been unable to acquire themselves. <p> | ||
+ | |||
+ | We also completed and shared the surveys of various teams! <p> | ||
+ | |||
+ | You can find out more about our collaborations <a href="https://2016.igem.org/Team:Oxford/Collaborations">here.</a></p><br> | ||
<div class="h4Purple"> | <div class="h4Purple"> | ||
− | Demonstrate how your team has identified, investigated and addressed one or more questions relating to human | + | Demonstrate how your team has identified, investigated and addressed one or more questions relating to human practices.</div> |
<p> | <p> | ||
− | There are ethical and safety concerns regarding the use of a probiotic therapeutic. We discussed these issues with the Professor of Health, Law and Policy Jane Kaye. Following her advice | + | There are ethical and safety concerns regarding the use of a probiotic therapeutic. We discussed these issues with the Professor of Health, Law and Policy: Jane Kaye. Following her advice, we went to the public to discover their concerns. This acted as a springboard for our ethics and safety research. </p> |
− | + | ||
− | + | <p> Throughout the project we aimed to educate and engage the public on a local, national and international level! </p> | |
− | + | ||
− | + | <p> We also heavily integrated discussions with patients and doctors into our design. </p> | |
+ | |||
+ | <p> Find out more <a href="https://2016.igem.org/Team:Oxford/HP/Silver">here!</a></p> | ||
+ | |||
</section> | </section> | ||
<section id="Gold"> | <section id="Gold"> | ||
<h2><font color="#FFD700">Gold</font></h2> | <h2><font color="#FFD700">Gold</font></h2> | ||
+ | <div class="h4Purple"> | ||
+ | Integrate the human practice issues into the design and/or execution of your project. </div> | ||
<p> | <p> | ||
− | + | From inception to execution, our Human Practice work has continually shaped our project. In creating a probiotic therapeutic, the opinions and thoughts of the public have continually been of huge importance, influencing the development of the project with regards to safety and ethics. However, our major concern was ensuring that our design met the needs and desires of Wilson’s Disease sufferers, to see how we integrated these discussions into our design, click <a href="https://2016.igem.org/Team:Oxford/HP/Gold">here.</a> | |
− | </p> | + | </p> <br> |
+ | |||
+ | <div class="h4Purple"> | ||
+ | Improve the function/characterisation of an existing BioBrick Part or Device. </div> | ||
+ | <p> | ||
+ | We have improved the function and characterisation of BBa_I760005, BBa_K190020, and BBa_K1758324. Click <a href="https://2016.igem.org/Team:Oxford/Description#Improve"> here </a> to see how! | ||
+ | </p> <br> | ||
+ | |||
+ | <div class="h4Purple"> | ||
+ | Demonstrate a functional proof of concept. </div> | ||
+ | <p> | ||
+ | A key goal of our project was to produce a functional proof of concept: demonstrating that at least one of our promoter-driven devices was sensitive to copper, and that the addition of copper to a bacterial population containing this device would induce a measurable amount of protein expression. To see how we achieved this, click <a href="https://2016.igem.org/Team:Oxford/Proof">here!</a> | ||
+ | |||
+ | |||
+ | |||
</section> | </section> | ||
Latest revision as of 23:11, 16 November 2016
![](https://static.igem.org/mediawiki/2016/8/83/Happy_team_photo_Oxford_2016_Sam.jpeg)
We were nominated for: Best Therapeutic Project,
Best Wiki, Best Presentation and
Best Education & Public Engagement!
- Developed an initial proof of concept for a Wilson’s Disease therapeutic as an alternative to current treatments, which have problems associated with their cost, side-effects and high dosage frequency.
- We added 13 new BioBrick parts to the iGEM registry. Check our parts page for more information.
- We investigated several different promoters and two different copper chelators with the aim of finding the most effective system.
- We successfully designed composite parts with a copper chelator under control of a copper-sensitive promoter. Check out our results page for more information.
- Discussions with the wider community played a major role in our project. We spoke to doctors and patients about Wilson’s Disease and used their feedback to guide our project. Check out our Human Practices Hub for more information.
Bronze
We’re ready for Boston in every way after the summer of our lives. Counting down the days to the Giant Jamboree!
All submitted with love and hard work. Our judging form is here.
We have many to thank and you can find out about them here.
BBa_K1980000 and BBa_K1980001 are both are new to the Registry. Find out more about them on our Parts page.
Silver
BBa_K1980003, BBa_K1980005, BBa_K1980007, BBa_K1980008 and BBa_K1980012 work as expected, hooray! See more information here.
We carried out all of the modelling for the Vilnius-Lithuania iGEM team, which can be seen on their wiki. Additionally, we carried out a joint survey with the team, who have also been investigating a potential probiotic therapeutic, to investigate the perspectives of different cultures to probiotics and their application.
We sent XMU China parts generated by last year’s Oxford iGEM team that they had been unable to acquire themselves.
We also completed and shared the surveys of various teams!
You can find out more about our collaborations here.
There are ethical and safety concerns regarding the use of a probiotic therapeutic. We discussed these issues with the Professor of Health, Law and Policy: Jane Kaye. Following her advice, we went to the public to discover their concerns. This acted as a springboard for our ethics and safety research.
Throughout the project we aimed to educate and engage the public on a local, national and international level!
We also heavily integrated discussions with patients and doctors into our design.
Find out more here!
Gold
From inception to execution, our Human Practice work has continually shaped our project. In creating a probiotic therapeutic, the opinions and thoughts of the public have continually been of huge importance, influencing the development of the project with regards to safety and ethics. However, our major concern was ensuring that our design met the needs and desires of Wilson’s Disease sufferers, to see how we integrated these discussions into our design, click here.
We have improved the function and characterisation of BBa_I760005, BBa_K190020, and BBa_K1758324. Click here to see how!
A key goal of our project was to produce a functional proof of concept: demonstrating that at least one of our promoter-driven devices was sensitive to copper, and that the addition of copper to a bacterial population containing this device would induce a measurable amount of protein expression. To see how we achieved this, click here!